Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Franzetti

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Plos One|January 12, 2016
HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug UsersAlessia Lai, Giorgio Bozzi, Marco Franzetti, et al.
AIDS Research and Human Retroviruses|January 9, 2010
Transmitted HIV Type 1 drug resistance and Non-B subtypes prevalence among seroconverters and newly diagnosed patients from 1992 to 2005 in ItalyChiara Riva, Alessia Lai, Ilaria Caramma, et al.
Plos One|August 10, 2012
HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South AmericaAlessia Lai, Francesco R Simonetti, Gianguglielmo Zehender, et al.
International Journal of Antimicrobial Agents|December 6, 2014
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillanceGiordano Madeddu, Giuseppe V L De Socio, Elena Ricci, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 6, 2021
IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational StudyMarco Franzetti, Andrea Forastieri, Noemi Borsa, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 26, 2013
Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project)Barbara Menzaghi, Elena Ricci, Laura Carenzi, et al.
Plos One|July 19, 2012
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experienceAmedeo Capetti, Simona Landonio, Paola Meraviglia, et al.
International Journal of Antimicrobial Agents|December 10, 2013
Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E StudyAmedeo Capetti, Paola Meraviglia, Simona Landonio, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 8, 2025
Real-world use of cefiderocol as monotherapy or combination therapy for the treatment of Gram-negative bacterial infections: the multicentre retrospective CEFI-BAC studyMatteo Augello, Francesca Di Bartolomeo, Benedetta Varisco, et al.
Chest|April 15, 2021
Hospital-Acquired Infections in Critically Ill Patients With COVID-19Giacomo Grasselli, Vittorio Scaravilli, Davide Mangioni, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Plos One|January 12, 2016
HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug UsersAlessia Lai, Giorgio Bozzi, Marco Franzetti, et al.
AIDS Research and Human Retroviruses|January 9, 2010
Transmitted HIV Type 1 drug resistance and Non-B subtypes prevalence among seroconverters and newly diagnosed patients from 1992 to 2005 in ItalyChiara Riva, Alessia Lai, Ilaria Caramma, et al.
Plos One|August 10, 2012
HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South AmericaAlessia Lai, Francesco R Simonetti, Gianguglielmo Zehender, et al.
International Journal of Antimicrobial Agents|December 6, 2014
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillanceGiordano Madeddu, Giuseppe V L De Socio, Elena Ricci, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 6, 2021
IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational StudyMarco Franzetti, Andrea Forastieri, Noemi Borsa, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 26, 2013
Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project)Barbara Menzaghi, Elena Ricci, Laura Carenzi, et al.
Plos One|July 19, 2012
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experienceAmedeo Capetti, Simona Landonio, Paola Meraviglia, et al.
International Journal of Antimicrobial Agents|December 10, 2013
Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E StudyAmedeo Capetti, Paola Meraviglia, Simona Landonio, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 8, 2025
Real-world use of cefiderocol as monotherapy or combination therapy for the treatment of Gram-negative bacterial infections: the multicentre retrospective CEFI-BAC studyMatteo Augello, Francesca Di Bartolomeo, Benedetta Varisco, et al.
Chest|April 15, 2021
Hospital-Acquired Infections in Critically Ill Patients With COVID-19Giacomo Grasselli, Vittorio Scaravilli, Davide Mangioni, et al.
Pageof 5